Variability in Clinical Performance of the FDA-Cleared Lumipulse P-Tau217/β-Amyloid 1-42 Plasma Ratio

Alicia Algeciras-Schimnich; Joshua A. Bornhorst; Daniel J. Figdore; Ramiro Eduardo Rea Reyes; Susan Ashrafzadeh-Kian; Rachel Wilson; Miller MD; D H Johnson; Hugo Botha; Stuart J. McCarter; Gregory S. Day; Jonathan Graff-Radford; Vijay K. Ramanan; Clifford R. Jack; Sterling C. Johnson; Henrik Zetterberg; Ronald C. Petersen

doi:10.1001/jamaneurol.2026.1565

June 1, 2026JAMA Neurology

Variability in Clinical Performance of the FDA-Cleared Lumipulse P-Tau217/β-Amyloid 1-42 Plasma Ratio

View at Publisher

Ask AI

Bookmark

Share

Key Points

This research aims to assess the effectiveness of p-tau217 to β-amyloid plasma ratio cut points in identifying amyloid pathology linked to Alzheimer disease.
Cross-sectional study design
Evaluation of FDA-cleared phosphorylated tau 217 (p-tau217) to β-amyloid 42 ratio
Focus on detecting amyloid pathology in relation to Alzheimer disease
From the evaluated population, variability was observed in the performance of p-tau217 to β-amyloid ratio in detecting amyloid pathology.
Specific cut points associated with varied sensitivity and specificity for Alzheimer disease diagnosis.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Cross-sectional study evaluates p-tau217 to beta-amyloid plasma ratio in Alzheimer disease, indicating variable performance effectiveness.

Abstract

This cross-sectional study evaluates the performance of the US Food and Drug Administration–cleared phosphorylated tau 217 (p-tau217) to β-amyloid 42 ratio cut points used to detect amyloid pathology associated with Alzheimer disease.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Algeciras-Schimnich et al. (2026) studied this question.

synapsesocial.com/papers/6a1fc42cdee9eb8c0dce5b71 https://doi.org/10.1001/jamaneurol.2026.1565

View at Publisher

Ask AI

Bookmark

Share

Variability in Clinical Performance of the FDA-Cleared Lumipulse P-Tau217/β-Amyloid 1-42 Plasma Ratio

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Variability in Clinical Performance of the FDA-Cleared Lumipulse P-Tau217/β-Amyloid 1-42 Plasma Ratio

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading